-
Talabostat Mesylate (PT-100): Mechanism & Evidence
2026-09-03
Talabostat mesylate, also called PT-100, is an orally active inhibitor of DPP4 and fibroblast activation protein (FAP). Product and cellular evidence support target engagement and immune-stromal research applications, but the available breast-cancer xenograft result did not show statistically significant tumor-growth inhibition.
-
Ademetionine in Neurological Disorders: Review Insights
2026-09-02
The 1994 review by Bottiglieri, Hyland, and Reynolds connected impaired one-carbon metabolism with neuropsychiatric disease and evaluated ademetionine (S-adenosylmethionine; SAMe) as a potential intervention. Its main contribution was a biochemical-to-clinical framework linking methylation, monoamine signaling, vitamin B12 and folate status, depression, dementia, and remyelination, while also emphasizing the preliminary nature of much of the clinical evidence.
-
mCherry mRNA Workflows for Nanoparticle Assays
2026-09-02
Use mCherry mRNA as a quantitative reporter for nanoparticle loading, cellular delivery, and transient red fluorescent protein expression. Cap 1 capping, 5mCTP and ψUTP, and an optimized poly(A) tail make this reporter especially useful when assay sensitivity and low innate immune stimulation matter.
-
Antipyrine: A Smarter BBB Assay Control
2026-09-01
Antipyrine (1,5-dimethyl-2-phenylpyrazol-3-one) can do more than represent analgesic pharmacology: it can help researchers diagnose permeability, recovery, and barrier-integrity errors. This article translates a 2025 surrogate blood-brain barrier study into a decision framework for pharmacokinetic studies and drug metabolism research.
-
Pexmetinib: A Kinetic View of Cytokine Control
2026-09-01
Pexmetinib (ARRY-614) is more than a dual kinase inhibitor: it can serve as a mechanistic probe for separating target occupancy, p38α dephosphorylation, and cytokine output. This article translates recent structural findings into a causally resolved assay strategy for inflammation and myelodysplastic syndromes research.
-
Rapid Purification of Recombinant Annexin V
2026-08-31
Burger and colleagues developed a short, selective purification strategy for recombinant annexin V that combines mild osmotic opening of Escherichia coli with reversible calcium-dependent liposome binding and final ion-exchange chromatography. The approach produced highly pure protein suitable for electrophysiology, crystallography, electron microscopy, and related biophysical studies while reducing co-purification from bacterial disruption.
-
DCPS and m7G Regulation in Diabetic Foot Ulcers
2026-08-31
Xiao et al. identify the decapping scavenger enzyme DCPS as an m7G-related biomarker associated with impaired epithelial repair in diabetic foot ulcers. By integrating transcriptomic analysis with keratinocyte experiments, the study connects reduced DCPS to cell-cycle disruption, weaker proliferation and migration, and increased apoptosis, while also defining important limits for clinical translation.
-
IEM 1460: From AMPA Blockade to Translation
2026-08-30
IEM 1460 provides a selective way to interrogate AMPA receptor signaling, linking fast excitatory transmission to excitotoxicity and neuroprotection hypotheses. This thought-leadership analysis positions the compound as a mechanistic research tool and explains how evidence from the related dual antagonist IEM-1925 can inform, but not substitute for, IEM 1460-specific validation.
-
GS967: Cardiac Late Sodium Current Workflows
2026-08-29
GS967 is a cardiac late sodium current inhibitor for connecting pathological Na⁺ influx with prolonged repolarization, calcium mishandling, impaired relaxation, and arrhythmia. This practical guide covers ventricular myocyte recordings, aging models, isolated-heart assays, ischemia-induced arrhythmia studies, and troubleshooting strategies.
-
BMS 309403: FABP4 Inhibitor Workflow
2026-08-28
BMS 309403 provides a selective, mechanism-focused way to connect FABP4 activity with lipid accumulation, macrophage inflammation, and metabolic phenotypes. This guide translates recent SERCA2–calcineurin–FoxO1–FABP4 findings into practical cell-based workflows, controls, and troubleshooting strategies.
-
Gramine–CUL3–MTDH Axis in TNBC Ferroptosis
2026-08-28
A 2026 study identifies Gramine as a potential ferroptosis inducer that suppresses triple-negative breast cancer through a CUL3–MTDH ubiquitination mechanism. Its integrated chemical, cellular, and mouse-model experiments provide a framework for studying how target engagement and ubiquitin-pathway regulation can be connected to ferroptotic cell death.
-
Nav1.5 Ser571 Phosphorylation in Cardiac Aging
2026-08-27
The 2024 reference study identifies Nav1.5 phosphorylation at Ser571 as a mechanistic link between increased late sodium current, delayed ventricular repolarization, and impaired diastolic function during cardiac aging. By combining phosphomimetic and phosphoablated mouse models with electrophysiology, calcium imaging, and contractility measurements, the work moves beyond association and shows how late sodium current can organize both electrical and mechanical features of the aging myocardium.
-
Fenofibrate: From PPARα to YAP Assays
2026-08-27
Fenofibrate is a PPARα agonist whose effects extend from lipid metabolism to liver growth and cancer-model phenotypes. This article presents an assay-centered framework for separating receptor pharmacology, YAP signaling, formulation, and interpretation.
-
BMAL1 Phase Separation and Circadian Transcription
2026-08-26
The reference study identifies BMAL1 as a phase-separating transcription factor that forms dynamic nuclear condensates and organizes CLOCK, p300, and MED1 at E-box DNA. Its deletion and rescue experiments connect an N-terminal intrinsically disordered region, phosphorylation-sensitive condensation, and transcriptional output to circadian behavior, providing a mechanistic explanation for how BMAL1 occupancy can be separated in time from gene activation.
-
Betacoronaviruses Rewire the Integrated Stress Response
2026-08-26
This bioRxiv preprint compares HCoV-OC43, SARS-CoV-2, and MERS-CoV to show that related betacoronaviruses engage PERK–eIF2α signaling differently during infection. The findings identify virus-specific dependence on eIF2α dephosphorylation, with implications for interpreting host-directed antiviral strategies and protein phosphorylation signaling.